RepliCel Life Sciences Book/Share
What is the Book/Share of RepliCel Life Sciences?
The Book/Share of RepliCel Life Sciences, Inc. is -0.08
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with book/share similar to RepliCel Life Sciences
- Sophiris Bio Inc has Book/Share of -0.08
- Clean Power Hydrogen Plc has Book/Share of -0.08
- Inspire Semiconductor has Book/Share of -0.08
- Rentian Technology has Book/Share of -0.08
- Wenye has Book/Share of -0.08
- Seelos Therapeutics has Book/Share of -0.08
- RepliCel Life Sciences has Book/Share of -0.08
- National Investments Fund has Book/Share of -0.08
- Minnova has Book/Share of -0.08
- Spackman Equities has Book/Share of -0.08
- Catenae Innovation Plc has Book/Share of -0.08
- Comtec Solar Systems has Book/Share of -0.08
- MX Gold has Book/Share of -0.08